Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia

Visual Acuity Clinical Trial

Official title:

Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04073186
• Other study ID #: CR-6349
• Status: Completed
• Phase: N/A
• Start date: August 7, 2019
• Est. completion date: March 20, 2020

Study information

• Verified date: August 2022
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-masked, dispensing clinical trial. A total of approximately 48 myopic and 32 hyperopic eligible subjects will be targeted to complete the study. Subjects will be fit in the study lens, optimized if required and worn for approximately 2 weeks. Subjects will then have a washout period of approximately 1 week and be refit in the lenses and be dispensed for an additional 2 weeks of wear.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 91
• Est. completion date: March 20, 2020
• Est. primary completion date: March 20, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Potential subjects must satisfy all the following criteria to be enrolled in the

study:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.

3. The subject must be between 40 and 70 years of age at the time of screening.

4. Subjects must own a wearable pair of spectacles if required for their distance vision.

5. The subject must be an adapted monovision soft contact lens wearer in both eyes (i.e., worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration).

6. The subject's distance spherical equivalent refraction must be in the range of +3.50 D to -4.00 D in each eye.

7. The subject's refractive cylinder must be =1.00 D in each eye.

8. The subject's ADD power must be in the range of +0.75 D to +2.50 D.

9. The subject must have best corrected distance visual acuity of 20/20-3 or better in each eye.

Exclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from

participating in the study:

1. Currently Pregnant or lactating.

2. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g., hepatitis, tuberculosis).

3. Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), systemic steroids.

4. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, dacryocystorhinostomy, etc.).

5. Use of any ocular medication, with the exception of rewetting drops.

6. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.

7. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).

8. Any known hypersensitivity or allergic reaction to OPTI-FREE® Puremoist® care cleaning solution, non-preserved rewetting drop solution or sodium fluorescein.

9. History of herpetic keratitis.

10. Entropion, ectropion, chalazia, glaucoma, history of recurrent corneal erosions.

11. A history of amblyopia, strabismus or binocular vision abnormality.

12. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.

13. Any ocular infection or inflammation.

14. Any ocular abnormality that may interfere with contact lens wear.

15. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.

Related Conditions & MeSH terms

• Presbyopia
• Visual Acuity

Intervention

Device:
• ACUVUE® OASYS with Transitions™
JJVC Marketed Contact Lens

Locations

Country	Name	City	State
United States	Western Reserve Vision Care, Inc.	Beachwood	Ohio
United States	VRC-East	Jacksonville	Florida
United States	Manhattan Vision Associates	New York	New York
United States	Advanced Eyecare	Raytown	Missouri
United States	Dr. David W. Ferris & Associates	Warwick	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vision Scores	Vision Scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.	2-Week Follow-up
Primary	Visual Performance (logMAR)	Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be etween 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64 cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2).; Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.	2-Week Follow-up
Secondary	CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle	Vision Scores wwere assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.	Up to 2-Week Follow-up